Compare
AbbVie vs Vertex Pharmaceuticals (ABBV vs VRTX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Vertex Pharmaceuticals (VRTX) +31.2%; so far this year the figures are +27.5% and +20.7%.
AbbVie is the larger company by market value, about 3.7 times the size of Vertex Pharmaceuticals.
On trailing earnings, ABBV trades at 50.1 times and VRTX at 35.2 times.
Revenue grew +10.7% at ABBV and +10.5% at VRTX over the last year.
ABBV yields 2.38%. VRTX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | VRTX | |
|---|---|---|
| Price | $291.31 | $547.09 |
| 1-day | +1.07% | +0.85% |
| YTD | +27.49% | +20.67% |
| 1 year | +34.39% | +31.20% |
| 3 years | +104.47% | +48.13% |
| Market cap | $514.9B | $138.7B |
| P/E | 50.1 | 35.2 |
| P/S | 7.80 | 10.71 |
| P/B | — | 6.63 |
| Revenue growth | +10.70% | +10.50% |
| EPS growth | +340.20% | +9.30% |
| Gross margin % | 73.7 | 85.5 |
| Net margin % | 15.7 | 30.7 |
| ROE % | — | 19.0 |
| Debt / equity | — | 0.22 |
| FCF yield % | 3.7 | 2.3 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.45 |
| RSI (14) | 59.7 | 58.0 |
| Technical rating |